BLTE Initiates Rolling NDA Submission for Tinlarebant in Stargardt Disease, Targets Q2 2026 Completion, Breakthrough Therapy Designation
Belite Bio, Inc American Depositary Shares · Now $147.00
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS